Staphylococcus haemolyticus palm infection in an apparently healthy adult
Vathsala Mohan A * , Clay Golledge A , Jonathan Grasko B and Yael Grasko BA
B
Dr Vathsala (Ala) Mohan has a PhD in molecular epidemiology from Massey University, New Zealand, and has vast experience in biomedical sectors like recombinant DNA technology, immuno‐diagnostics and reproductive biotechnology. Ala’s expertise includes human gut health and nutrition, human pathogens and food safety. Previous roles include Operations and Technical Manager (Livestock Improvement Corporation, New Zealand), SARS‐CoV2diagnostic medical lab scientist (Auckland Health District Board, New Zealand), and senior medical laboratory scientist and Quality Assurance Manager for National Association of Testing Authorities (NATA), WA, Australia. Currently Ala is contributing to CSIRO’s antimicrobial resistance research. |
Clay Golledge is the Executive Director at Infections West, Hollywood Medical Centre. Clay has worked as a Senior Consultant in microbiology at the Health Department Western Australia and PathWest Sir Charles Gairdner Hospital (SCGH). |
Jonathan Grasko is a chemical pathologist and managing director of Saturn Pathology. Jonathan has expertise in toxicology and served in different pathology services as a chemical and toxicology expert for more than a decade. |
Yael Grasko is a chemical pathologist and has a business management specialisation. Yael is the medical director of Saturn Pathology and has worked as a chemical pathologist at QML Pathology Services and other pathology facilities for more than a decade. |
Abstract
A Staphylococcus haemolyticus strain has been isolated from the palm infection of an allied-health professional aged 35, who was otherwise healthy and without any known health issues. Microbial culture, MALDI-TOF species identification and susceptibility tests were included. The isolated strain was resistant to ampicillin and amoxycillin; however, the patient quickly responded after commencement of treatment with sulfamethoxazole and trimethoprim.
Keywords: amoxycillin resistance, ampicillin, antibiotic susceptibility, coagulase negative, commensal, culture, MALDI‐TOF, palm infection, Staphylococcus haemolyticus.
Dr Vathsala (Ala) Mohan has a PhD in molecular epidemiology from Massey University, New Zealand, and has vast experience in biomedical sectors like recombinant DNA technology, immuno‐diagnostics and reproductive biotechnology. Ala’s expertise includes human gut health and nutrition, human pathogens and food safety. Previous roles include Operations and Technical Manager (Livestock Improvement Corporation, New Zealand), SARS‐CoV2diagnostic medical lab scientist (Auckland Health District Board, New Zealand), and senior medical laboratory scientist and Quality Assurance Manager for National Association of Testing Authorities (NATA), WA, Australia. Currently Ala is contributing to CSIRO’s antimicrobial resistance research. |
Clay Golledge is the Executive Director at Infections West, Hollywood Medical Centre. Clay has worked as a Senior Consultant in microbiology at the Health Department Western Australia and PathWest Sir Charles Gairdner Hospital (SCGH). |
Jonathan Grasko is a chemical pathologist and managing director of Saturn Pathology. Jonathan has expertise in toxicology and served in different pathology services as a chemical and toxicology expert for more than a decade. |
Yael Grasko is a chemical pathologist and has a business management specialisation. Yael is the medical director of Saturn Pathology and has worked as a chemical pathologist at QML Pathology Services and other pathology facilities for more than a decade. |
References
1 Becker K et al. (2014) Coagulase-negative staphylococci. Clin Microbiol Rev 27, 870-926.
| Crossref | Google Scholar | PubMed |
2 Czekaj T et al. (2015) Staphylococcus haemolyticus – an emerging threat in the twilight of the antibiotics age. Microbiology (Reading) 161, 2061-2068.
| Crossref | Google Scholar | PubMed |
3 Silva PV et al. (2013) The antimicrobial susceptibility, biofilm formation and genotypic profiles of Staphylococcus haemolyticus from bloodstream infections. Mem Inst Oswaldo Cruz 108, 812-813.
| Crossref | Google Scholar | PubMed |
4 Takeuchi F et al. (2005) Whole-genome sequencing of Staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. J Bacteriol 187, 7292-7308.
| Crossref | Google Scholar | PubMed |
5 Froggatt JW et al. (1989) Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob Agents Chemother 33, 460-466.
| Crossref | Google Scholar | PubMed |
6 Clinical and Laboratory Standards Institute (2024) CLSI M100. Performance Standards for Antimicrobial Susceptibility Testing, 34th edn. CLSI. https://clsi.org/standards/products/microbiology/documents/m100/
